iRadimed Corporation (NASDAQ:IRMD) Director Monty K. Allen sold 1,898 shares of iRadimed stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $13.95, for a total transaction of $26,477.10. Following the completion of the transaction, the director now directly owns 9,062 shares in the company, valued at approximately $126,414.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of iRadimed Corporation (NASDAQ IRMD) remained flat at $$13.60 during mid-day trading on Wednesday. The company’s stock had a trading volume of 7,702 shares, compared to its average volume of 39,761. iRadimed Corporation has a one year low of $7.85 and a one year high of $15.00. The firm has a market cap of $143.02, a P/E ratio of 104.23 and a beta of 1.61.
iRadimed (NASDAQ:IRMD) last announced its earnings results on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.35. iRadimed had a net margin of 6.51% and a return on equity of 4.58%. The business had revenue of $5.69 million for the quarter, compared to analyst estimates of $5.60 million. During the same quarter in the previous year, the firm posted $0.14 earnings per share. iRadimed’s revenue was down 25.9% compared to the same quarter last year. analysts expect that iRadimed Corporation will post 0.05 earnings per share for the current fiscal year.
A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Credit Suisse Group assumed coverage on shares of iRadimed in a research report on Monday, November 27th. They issued a “buy” rating and a $19.00 price target on the stock. Roth Capital assumed coverage on shares of iRadimed in a research report on Tuesday, October 31st. They issued a “buy” rating and a $16.00 price target on the stock. Finally, ValuEngine raised shares of iRadimed from a “sell” rating to a “hold” rating in a research report on Friday, October 6th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $15.33.
WARNING: “iRadimed Corporation (IRMD) Director Monty K. Allen Sells 1,898 Shares” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2017/12/06/iradimed-corporation-irmd-director-monty-k-allen-sells-1898-shares.html.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with MarketBeat.com's FREE daily email newsletter.